MDXH
$0.92
+$0.46 (99.13%)+99.13%
OpenLoading chart...
IndexN/A
Market Cap0.05B
Enterprise Value0.24B
Income$-0.01B
Sales$0.05B
EmployeesN/A
P/E-2.42
P/S1.66
P/B-14.77
P/C-15.43
EV/EBITDA-17.47
EV/SalesN/A
EPS (ttm)-0.38
EarningsN/A
Gross Margin59.74%
Oper. Margin-14.28%
Profit Margin-31.07%
Volume289.07M
Shs Outstand0.05B
Change99.13%
Dividend Est.N/A
Dividend Ex-DateN/A
Perf YTDN/A
Perf YearN/A
Perf 3YN/A
Perf 5YN/A
Perf 10YN/A
IPON/A
| Metric | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $90.05M | $70.19M | $37.05M | $22.24M | $18.46M | $11.79M | $28.34M | $40.51M |
| Cost of Revenue | $34.91M | $26.26M | $17.84M | $11.68M | $10.42M | $11.93M | $11.65M | $10.20M |
| Gross Profit | $55.14M | $43.93M | $19.22M | $10.56M | $8.04M | $-144.00K | $16.69M | $30.30M |
| Gross Margin | 61.23% | 62.58% | 51.87% | 47.50% | 43.58% | -1.22% | 58.88% | 74.81% |
| Operating Expenses | $79.86M | $71.26M | $57.12M | $37.41M | $35.17M | $43.02M | $48.78M | $42.58M |
| Operating Income | $-24.72M | $-27.33M | $-37.90M | $-26.84M | $-27.12M | $-43.17M | $-32.10M | $-12.27M |
| Operating Margin | -27.45% | -38.93% | -102.28% | -120.69% | -146.93% | -366.30% | -113.27% | -30.30% |
| Net Income | $-38.07M | $-43.10M | $-44.04M | $-29.00M | $-28.66M | $-43.10M | $-32.45M | $-12.29M |
| Net Margin | -42.28% | -61.40% | -118.86% | -130.41% | -155.27% | -365.72% | -114.51% | -30.33% |
| EPS (Basic) | $-0.78 | $-1.66 | $-2.78 | $-2.38 | $-3.44 | $-6.89 | $-5.63 | $-2.46 |
| EBITDA | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Stock Option Compensation Expense | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Price To Earnings Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Price To Sales Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Shares Outstanding | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Market Capitalization | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Metric | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|
| Cash & Short Term Investments | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Short Term Receivables | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Inventories | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Other Current Assets | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Current Assets | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Property, Plant & Equipment | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Investments and Advances | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Long-Term Note Receivable | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Intangible Assets | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Deferred Tax Assets | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Other Assets | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Assets | $157.33M | $129.13M | $119.14M | $75.07M | $31.86M | $40.63M | $65.48M | $58.52M |
| Short Term Debt Incl. Current Port. of LT Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Accounts Payable | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Income Tax Payable | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Other Current Liabilities | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Current Liabilities | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Long Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Provision for Risks Charges | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Deferred Tax Liabilities | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Other Liabilities | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Liabilities | $142.49M | $121.92M | $109.82M | $28.17M | $26.01M | $20.90M | $13.36M | $14.97M |
| Non-Equity Reserves | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Preferred Stock - Carrying Value | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Common Equity | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Shareholders Equity | $14.84M | $7.21M | $9.31M | $46.90M | $5.85M | $19.72M | $52.12M | $43.55M |
| Accumulated Minority Interest | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Equity | $14.84M | $7.21M | $9.31M | $46.90M | $5.85M | $19.72M | $52.12M | $43.55M |
| Total Liabilities & Stockholders Equity | $157.33M | $129.13M | $119.14M | $75.07M | $31.86M | $40.63M | $65.48M | $58.52M |
| Book Value Per Share | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Tangible Book Value Per Share | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Full-Time Employees | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Price to Book Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Assets | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Equity | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Invested Capital | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Quick Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Current Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Metric | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|
| Net Income | $-38.07M | $-43.10M | $-44.04M | $-29.00M | $-28.66M | $-43.10M | $-32.45M | $-12.29M |
| Depreciation | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Other Funds (Non Cash) | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Funds from Operations | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Extraordinary Item | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Changes in Working Capital | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Income Taxes Payable | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Cash from Operating Activities | $-18.53M | $-21.50M | $-34.12M | $-22.55M | $-20.24M | $-22.29M | $-28.54M | $-10.49M |
| Capital Expenditures | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Assets From Acquisitions | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Sale of Fixed Assets and Businesses | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Purchase or Sale of Investments | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Purchase of Investments | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Sale Or Maturity of Investments | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Other Uses | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Other Sources | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Cash from Investing Activities | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Cash Dividends Paid | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Change in Capital Stock | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Repurchase of Common Pref Stock | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Sale of Common Pref Stock | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Proceeds from Stock Options | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Issuance or Reduction of Debt, Net | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Change in Long Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Issuance of Long Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Reduction of Long Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Financing Active Other Cash Flow | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Other Financing Activities Uses | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Cash from Financing Activities | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Exchange Rate Effect | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Change in Cash | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Free Cash Flow | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Preferred Dividends (Cash Flow) | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Price to Free Cash Flow | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Company coverage
Latest news
Mdxhealth Announces Receipt of Nasdaq Notification Regarding Minimum Market Value of Listed Securities DeficiencyGlobeNewswire Inc. Mdxhealth Reports Q1-2026 ResultsGlobeNewswire Inc. Mdxhealth Highlights Data from Oxford’s ProMPT Study Demonstrating the Genomic Prostate Score GPS Test Predicts Adverse Outcomes Across Multiple Treatment Settings at EAU 2026GlobeNewswire Inc. Mdxhealth to Present Fourth Quarter and Full Year 2025 Financial Results and Corporate Update on February 26GlobeNewswire Inc. MDxHealth Reports Preliminary Fourth Quarter and Full Year 2025 Revenues, Issues 2026 Revenue Guidance, and Amends Earnout Terms with Exact SciencesGlobeNewswire Inc. Mdxhealth and University of Oxford to validate GPS test in largest randomized trial of treatment effectiveness in patients with localized prostate cancerGlobeNewswire Inc. Mdxhealth Announces Closing of Exosome Diagnostics Acquisition from Bio-TechneBenzinga Mdxhealth Appoints Michael Holder to Board of Directors and Announces Management ChangeGlobeNewswire Inc.
Show 12 more stories
Global Molecular Diagnostics Market to Expand at a CAGR of ~9% by 2032 Due to the Rising Demand for Precision Medicine | DelveInsightGlobeNewswire Inc. Minimal Residual Disease Testing Market Forecast Report, 2025-2030 - Precision Medicine and Early Relapse Detection Drive MRD Testing Demand WorldwideGlobeNewswire Inc. Mdxhealth Announces Fourth Quarter and Full-Year 2024 Financial ResultsGlobeNewswire Inc. MDxHealth Reports Preliminary Fourth Quarter and Full Year 2024 Revenues and Issues 2025 Revenue GuidanceGlobeNewswire Inc. Liquid Biopsy Market to Reach $ 32.54 Billion, Globally, by 2033 at 11.61% CAGR: The Brainy InsightsGlobeNewswire Inc. Laboratory-Developed Tests (LDTs) World Market Forecast Report to 2028, with Coverage of the Effects of the FDA's New "Medical Devices: Laboratory Developed Tests" Rule, Passed in April 2024GlobeNewswire Inc. MDxHealth Reports Q1-2024 Results and Announces Growth Capital from OrbiMedGlobeNewswire Inc. Mdxhealth Adds Hereditary Prostate Cancer Genetic Test to Prostate Cancer OfferingGlobeNewswire Inc. These Analysts Increase Their Forecasts On MDxHealth After Q4 ResultsBenzinga Mdxhealth Announces Fourth Quarter and Full-Year 2023 Financial ResultsGlobeNewswire Inc. Agiliti (AGTI) Q4 Earnings Beat EstimatesZacks Investment Research DermTech, Inc. (DMTK) Reports Q4 Loss, Misses Revenue EstimatesZacks Investment Research
Insider Trading
No insider trades found for MDXH.
Company
About the company
MDxHealth SA is a commercial-stage precision diagnostics firm delivering specialized urologic solutions across the globe. Its international footprint includes the United States, various European nations such as the Netherlands, Belgium, Spain, Poland, Italy, and the wider European Union. The company's innovative genomic testing portfolio for prostate cancer comprises SelectMDx, a non-invasive urine test, and ConfirmMDx, an epigenetic diagnostic tool. These advanced offerings enable medical professionals to precisely identify clinically significant prostate cancer, thereby minimizing reliance on invasive procedures and their associated risks. Established in 2003, with its headquarters in Herstal, Belgium, the entity was formerly known as OncoMethylome Sciences SA until its renaming to MDxHealth SA in October 2010.
Discover more
You may be interested in